Genetic Analysis AS (XSAT:GEAN) Operating Margin %: -109.85% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:GEAN Genetic Analysis AS XSAT:GEAN
34 GF Score
Price kr0.66
GF Value kr0.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS Operating Margin %?

Genetic Analysis AS XSAT:GEAN -2.94% 34 Operating Margin % is -109.85% as of Mar. 2026. GuruFocus rates XSAT:GEAN with a GF Score™ of 34/100 and a GF Value™ of kr0.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Genetic Analysis AS ranks worse than 77.83% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genetic Analysis AS's Operating Income for the three months ended in Mar. 2026 was kr-4.23 Mil. Genetic Analysis AS's Revenue for the three months ended in Mar. 2026 was kr3.85 Mil. Therefore, Genetic Analysis AS's Operating Margin % for the quarter that ended in Mar. 2026 was -109.85%.

Good Sign:

Genetic Analysis AS operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Genetic Analysis AS's Operating Margin % or its related term are showing as below:

XSAT:GEAN' s Operating Margin % Range Over the Past 10 Years
Min: -424.57   Med: -164.06   Max: -60.41
Current: -60.41


XSAT:GEAN's Operating Margin % is ranked worse than
77.83% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.35 vs XSAT:GEAN: -60.41

Genetic Analysis AS's 5-Year Average Operating Margin % Growth Rate was 33.00% per year.

Genetic Analysis AS's Operating Income for the three months ended in Mar. 2026 was kr-4.23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.97 Mil.


Genetic Analysis AS  (XSAT:GEAN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genetic Analysis AS Operating Margin % Related Terms


Genetic Analysis AS Operating Margin % Historical Data

* Premium members only.

The historical data trend for Genetic Analysis AS's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Analysis AS Operating Margin % Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -424.57 -252.48 -164.06 -86.15 -62.12

Genetic Analysis AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -178.25 -14.18 -153.06 -43.04 -109.85

XSAT:GEAN vs TMO, DHR, IDXX: Operating Margin % Comparison

For the Diagnostics & Research subindustry, Genetic Analysis AS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Operating Margin % falls into.


XSAT:GEAN
34GF Score
Genetic Analysis AS XSAT:GEAN
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Analysis AS Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genetic Analysis AS's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-10.382 / 16.712
=-62.12 %

Genetic Analysis AS's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-4.228 / 3.849
=-109.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -109.85% mean?
Genetic Analysis AS (XSAT:GEAN) has a Operating Margin % of -109.85% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #158 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 77.8%.
Is Genetic Analysis AS's Operating Margin % too high?
Genetic Analysis AS's current Operating Margin % is -109.85%. Based on the distribution chart, Genetic Analysis AS ranks #158 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #158 out of 203 companies for Operating Margin %. This places Genetic Analysis AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current Operating Margin % is -109.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current Operating Margin % is -109.85%. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Operating Margin % is -109.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54. GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.

Key valuation signals for XSAT:GEAN:

  • Operating Margin %: -109.85%
  • GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genetic Analysis AS Business Description

Other Exchanges 8V8:Germany
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score

Get the complete analysis for XSAT:GEAN

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.66
Price
kr0.54
GF Value